ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX …

SAN MATEO, Calif. … The KOL event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential …

Continue

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 84% regionally and is currently trending positivepositive.

100%

Media Trust Score100%

Read All

In

News